trial

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCTId NCT01981811
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2014-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-03
Primary completion
2014-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AripiprazoleIngestible Event Marker (IEM)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Shashank Rohatagi, PhDStudy Director

Sites

0 total

Linked catalysts

1
Adherence to Treatment, Safety and Tolerability Study of the Medical Information — primary completion2014-05

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2014-05
Status
WITHDRAWN
relationships
The graph out of here
drug
Aripiprazole
drug
Ingestible Event Marker (IEM)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Treatment Adherence and Compliance
indication
Bipolar 1 Disorder
indication
Nervous System Diseases
indication
investigator
Shashank Rohatagi, PhD
person